Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib + Azacitidine in Japanese Patients with MDS or CMML
NCT02201329Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of volasertib in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicities up to 57 days and Maximum Tolerated Dose up to 57 days. Started Aug 2014; status: completed.
02
Drugs
volasertib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02201329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201329.